BEER-SHEVA, Israel, May 20, 2024 – When you disable the brakes on a race car, it quickly crashes. Dr. Barak Rotblat wants to do something similar to brain cancer cells. He wants to disable their ability to survive glucose starvation. In fact, he wants to speed the tumor cells up, so they just as quickly die out. It is a novel approach to brain cancer based on a decade of research in his lab.
He and his students' and co-lead researcher Gabriel Leprivier of the Institute of Neuropathology at University Hospital Düsseldorf findings were just published in Nature Communications last week.
Until now, it was believed that cancer cells prioritized growth and rapid proliferation. However, it has been shown that there is less glucose in tumors vs. normal tissue. If cancer cells are solely focused on reproducing at the fastest possible rate, then they should be more dependent on glucose than regular cells. However, what if their absolute top priority is survival rather than exponential growth? Then, triggering a burst of growth under glucose starvation could lead to the cell running out of energy to survive and dying out.
"It is an intriguing insight that comes after a decade of research," explains Dr. Rotblat, "we may be able to target just the cancer cells and not regular cells at all, which would be a very promising step forward on the path to personalized medicine and therapeutics that do not affect healthy cells the way chemotherapy and radiation do."
"Our discovery about glucose starvation and the role of antioxidants opens a therapeutic window to pursue a molecule which could treat glioma (brain cancer)," he adds. Such a therapeutic might also be able to treat other types of cancers.
Rotblat and his students, Dr. Tal Levy and Dr. Khawla Alasad began by considering that cells regulate their growth according to their available energy. When energy is plentiful, cells make fat and lots of proteins to store energy and grow. When energy is scarce, they must pump the brakes and stop making fat and proteins or burn themselves out.
Tumors are mostly in a de facto state of glucose starvation. So, they began thinking about locating the molecular brakes that enable the cancer cell's survival in glucose starvation. If they could turn that off, then the tumor would die, but the regular cells, which are not glucose-starved, would remain unaffected.
So, Rotblat and his students followed the trail of a mTOR (Mamelian Target of Rapamycin) pathway. A pathway equipped with proteins that measure the energetic state of the cell and, accordingly, regulate cell growth. They found that a protein in the mTOR pathway, known to pump the brakes on protein synthesis when energy drops, 4EBP1, is essential for human, mouse, and even yeast cells, to survive glucose starvation. They demonstrated that 4EBP1 does so by negatively regulating the levels of a critical enzyme in the fatty acid synthesis pathway, ACC1. This mechanism is exploited by cancer cells, particularly brain cancer cells, to survive in tumor tissue and generate aggressive tumors.
Dr. Rotblat is now working with BGN Technologies and the National Institute for Biotechnology in the Negev to develop a molecule that will block 4EBP1 forcing glucose-starved tumor cells to keep making fat and burn themselves out when they are glucose-starved.
This work was supported by funds from the Israel Cancer Association (grant no. 20220143), the Israel Science Foundation (grant no. 1436/19) and the NIBN; the Dr. Rolf M. Schwiete Stiftung (grant no. 2020-018); the Deutsche Forschungsgemeinschaft (grant no. LE 3751/2-1), the German Cancer Aid (grants no. 70112624 and 70115129), the Elterninitiative Düsseldorf e.V. (grant no. 701910003), and the Research Commission of the Medical Faculty, Heinrich Heine University Düsseldorf (grants no. 2016-056 and 2020-044); the Matthias-Lackas foundation, the Dr. Leopold und Carmen Ellinger foundation, the European Research Council (ERC CoG 2023 #101122595), Dr. Rolf M. Schwiete foundation (2021-007, 2022-31), the Deutsche Forschungsgemeinschaft (DFG 458891500), the German Cancer Aid (DKH-7011411, DKH-70114278, DKH-70115315, DKH-70115914), the SMARCB1 association, the Ministry of Education and Research (BMBF; SMART-CARE and HEROES-AYA), the Fight Kids Cancer foundation (FKC-NEWtargets), the KiTZ-Foundation in memory of Kirstin Diehl, the KiTZ-PMC twinning program, the German Cancer Consortium (DKTK, PRedictAHR), and the Barbara and Wilfried Mohr foundation; the German Cancer Aid (DKH-70114131) and the German Academic Scholarship Foundation; the European Research Council under the ERC Consolidator Grant Agreement n. 771486–MetaRegulation, FWO—Research Projects (G098120N and G0B4122N), KU Leuven—FTBO (ENN-OZFTBO-P7015), King Baudouin Foundation (2021-J1990112-22260), Beug Foundation (Metastasis Prize 2021) and Fonds Baillet Latour (Grant for Biomedical Research 2020).
